Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Psoriasis

Psoriasis

Subtypes of Psoriasis

Plaque psoriasis 18 Inverse Psoriasis 2 Erythrodermic psoriasis 1 Generalized pustular psoriasis 1

56 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Psoriasis

289 trials tracked for Psoriasis: 148 in phase 3 or 4 and 52 with published results. The most-cited published study has 852 citations.

289Trials tracked
148Phase 3 & 4
0Recruiting
52With published results
Phase distribution
Phase 4 50 Phase 3 98 Phase 2 85 Phase 1 21 Other / NA 35
  1. Phase 3 A Phase 3 Study in Participants With Moderate to Severe Psoriasis Completed · 852 cited
  2. Phase 4 Mechanism of Action Study for Psoriasis Completed · 728 cited
  3. Phase 3 Etanercept (Enbrel®) in Psoriasis - Pediatrics Completed · 391 cited
  4. Phase 3 A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis Completed · 381 cited
  5. Phase 3 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 302 cited
  6. Phase 3 BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment Completed · 217 cited
Show 44 more trials
  1. Phase 3 An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 157 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 157 cited
  3. Phase 4 Vascular Inflammation in Psoriasis - Extension Study Completed · 151 cited
  4. Phase 4 Vascular Inflammation in Psoriasis Trial (The VIP Trial) Completed · 151 cited
  5. Phase 3 A Study in Japanese Participants With Moderate-to-Severe Psoriasis Completed · 132 cited
  6. Phase 3 Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) Completed · 131 cited
  7. Phase 3 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis Completed · 89 cited
  8. Phase 3 Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis Completed · 88 cited
  9. Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Completed · 86 cited
  10. Phase 3 A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis Completed · 84 cited
  11. Phase 3 Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis Completed · 81 cited
  12. Phase 3 A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) Completed · 71 cited
  13. Phase 3 A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis Completed · 70 cited
  14. Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Completed · 58 cited
  15. Phase 3 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Completed · 58 cited
  16. Phase 3 A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab Completed · 58 cited
  17. Phase 3 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 57 cited
  18. Phase 3 Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy Completed · 57 cited
  19. Phase 3 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 56 cited
  20. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 55 cited
  21. Phase 3 Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis Completed · 55 cited
  22. Phase 3 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp Completed · 51 cited
  23. Phase 3 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) Completed · 51 cited
  24. Phase 4 Vascular Inflammation in Psoriasis - Apremilast Completed · 50 cited
  25. Phase 3 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis Completed · 35 cited
  26. Phase 3 Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis Completed · 34 cited
  27. Phase 3 A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis Completed · 32 cited
  28. Phase 3 The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis Completed · 32 cited
  29. Phase 3 A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Completed · 31 cited
  30. Phase 3 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis Completed · 27 cited
  31. Phase 3 Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 23 cited
  32. Phase 3 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Completed · 22 cited
  33. Phase 4 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy Completed · 21 cited
  34. Phase 3 An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age Completed · 21 cited
  35. Phase 3 A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis Completed · 18 cited
  36. Phase 3 Study of Secukinumab With 2 mL Pre-filled Syringes Completed · 18 cited
  37. Phase 4 A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies Completed · 14 cited
  38. Phase 3 A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) Completed · 13 cited
  39. Phase 3 A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 13 cited
  40. Phase 4 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed · 9 cited
  41. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis Completed · 6 cited
  42. Phase 3 A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Completed · 4 cited
  43. Phase 4 A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life Completed · 3 cited
  44. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea Completed · 3 cited

Showing the 50 most-cited and recently-updated of 289 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Psoriasis: what the trials found

Secukinumab showed no significant difference in PASI 90 at week 28 compared to placebo (p=0.3857) but demonstrated a significant difference in PASI 75 over time (p=0.0300) 1. Risankizumab significantly improved PASI 90 and sPGA 0/1 at week 16 versus placebo (both p<0.001) 7. Deucravacitinib significantly improved DLQI 0/1, DLQI ≥4 reduction, and itch NRS at week 16 (p=0.0001 to p<0.0001) 14, and significantly improved scalp-specific outcomes (Ss-PGA 0/1, PSSI 90, scalp itch NRS) at week 16 (all p<0.0001) 16. Apremilast significantly improved DLQI ≥4 reduction and DLQI change at week 16 (p<0.0001) and BSA percent change (p=0.0085) 11. Tildrakizumab significantly improved quality of life (PGWB and DLQI) over time (p<0.001 to p=0.011) 10. Methotrexate showed significant improvement in biologic activity endpoints (p<0.05) and clinical endpoints (PASI 75: 67% vs 27%; PGA 0-1: 73% vs 27%) 3. Efalizumab resulted in 68% of patients achieving PGA good or better, with 11% rebound and 12.9% exacerbation 8; another trial reported 46% achieving PGA excellent or cleared at week 24 9. Tapinarof cream 1% led to 23% of patients achieving target lesion PGA clear/almost clear in head/neck 17 and 24% achieving intertriginous PGA clear/almost clear 18. Adalimumab showed no significant change in vascular inflammation or cardiometabolic biomarkers (p>0.05) 4. Apremilast showed no significant change in aortic vascular inflammation (p=0.612) or cardiometabolic markers (CRP p=0.617, ferritin p=0.083) 6. Tildrakizumab showed minimal change in coronary flow reserve (-0.03) and no significant correlation with skin severity (p=0.35) 13. Metaderm improved sPGA*BSA (53.06% vs 65.6%) and DLQI (52.88% vs 17.82%) 21. Apremilast improved nail psoriasis (mNAPSI mean percent change 64.1% at week 36, p=0.05) and nail pain VAS (-50.42%) 22. Secukinumab improved itch, pain, and PASI scores (change: 3, 2, 8 respectively) 15.

Recent results — preliminary, needs further review

  • Orticumab (phase 2, N=77) showed variable mean percent change in PASI across doses (-3.46 to -20.14) and low rates of PASI75/PASI50 (0-51%) and sIGA success (1 participant per group) 2.

For the clinician treating this condition

  • Risankizumab, deucravacitinib, and apremilast demonstrate significant improvements in skin clearance and quality of life measures.
  • Biologics like secukinumab and tildrakizumab also improve quality of life, though secukinumab's PASI 90 at week 28 was not significant.
  • Methotrexate remains effective for clinical endpoints, while apremilast shows benefit for nail psoriasis.
  • Cardiovascular outcomes with adalimumab, apremilast, and tildrakizumab did not show significant changes.

AI synthesis of 18 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
BAT2306 shows comparable efficacy and safety to secukinumab in moderate-to-severe plaque psoriasis
Dermatology RCT
BAT2306 shows comparable efficacy and safety to secukinumab in moderate-to-severe plaque psoriasis Trial shows BAT2306 performs similarly to secukinumab for plaque psoriasis
This Phase 3 randomized controlled trial evaluated 502 adults with moderate-to-severe plaque-type psoriasis. The study found that BAT2306 de…
A new clinical trial shows that the medication BAT2306 offers similar results and safety for plaque psoriasis compared to the established dr…
Sep 1, 2026
Older age, higher BMI, and comorbidities are associated with lower clearance rates in psoriasis patients
Dermatology Meta-analysis
Older age, higher BMI, and comorbidities are associated with lower clearance rates in psoriasis patients Factors Like Age and BMI Impact Psoriasis Treatment Success
This meta-analysis of 13,902 patients evaluates predictors of clinical response to biologic therapies in psoriasis. The analysis identifies …
New data shows that age, body mass index, and other health factors can influence how well patients with psoriasis respond to biologic therap…
Sep 1, 2026
IL-17 axis targeting shows substantial efficacy but faces cost and delivery hurdles
Drug Pipeline Sys. Review
IL-17 axis targeting shows substantial efficacy but faces cost and delivery hurdles IL-17 blockers show promise for autoimmune diseases
This systematic review examines IL-17 axis targeting with monoclonal antibodies and small-molecule inhibitors across psoriasis, lupus, perio…
New review finds IL-17-targeting drugs work well for psoriasis and other conditions, but cost and side effects remain hurdles.
Frontiers Aug 23, 2026
78 plasma proteins linked to psoriasis; 12 prioritized as potential drug targets
Genetics & Precision Medicine Meta-analysis
78 plasma proteins linked to psoriasis; 12 prioritized as potential drug targets 78 proteins linked to psoriasis may reveal new drug targets
This meta-analysis of genome-wide association studies (GWAS) identified 78 circulating proteins with genetically predicted associations with…
A large genetic study found 78 proteins tied to psoriasis, including 12 promising drug targets. This could lead to new treatments.
medRxiv Aug 22, 2026
Psoriasis patients with moderate to severe disease show higher prevalence of type 2 diabetes
Rheumatology Sys. Review
Psoriasis patients with moderate to severe disease show higher prevalence of type 2 diabetes Psoriasis patients face higher risk of type 2 diabetes
This narrative review explores the link between psoriasis and type 2 diabetes mellitus, highlighting shared inflammatory pathways and metabo…
People with psoriasis are more likely to develop type 2 diabetes because both conditions share common pathways of chronic inflammation.
Frontiers Aug 11, 2026
Chronic dermatologic conditions significantly impact psychological distress and health-related quality of life in pediatric patients
Pediatrics Meta-analysis
Chronic dermatologic conditions significantly impact psychological distress and health-related quality of life in pediatric patients Chronic skin conditions cause significant emotional distress in children
This systematic review of 41 studies examines the impact of chronic skin disorders on psychological outcomes and health-related quality of l…
Children with chronic skin conditions like psoriasis and eczema face high rates of anxiety, depression, and social struggles.
Frontiers Aug 5, 2026
GDF15 acts as a multi-node signaling hub in inflammatory skin diseases and systemic sclerosis
Neurology Sys. Review
GDF15 acts as a multi-node signaling hub in inflammatory skin diseases and systemic sclerosis Growth Factor GDF15 Linked to Skin Aging and Inflammation
This narrative review explores GDF15 as a signaling hub affecting melanocyte activity, fibroblast collagen synthesis, and the IL-23/Th17 axi…
A protein called GDF15 may play a key role in skin aging, pigmentation, and inflammatory conditions like psoriasis.
Frontiers Aug 2, 2026
Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis
Oncology Meta-analysis
Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis New data ranks different treatments for moderate to severe psoriasis
This systematic review and network meta-analysis of 27 RCTs evaluated IL-23/IL-17 inhibitors for moderate-to-severe plaque psoriasis. Guselk…
Comparing several types of biologics helps patients with plaque psoriasis find which medications rank highest for clearing skin and improvin…
Frontiers Jul 26, 2026
Obesity is associated with lower PASI90, PASI75, and PASI100 responses in patients with psoriasis
Diabetes & Endocrinology Meta-analysis
Obesity is associated with lower PASI90, PASI75, and PASI100 responses in patients with psoriasis Obesity May Impact How Well Certain Psoriasis Drugs Work
This meta-analysis of 4200 patients found that obesity is associated with lower PASI90 (RR = 0.64), PASI75 (RR = 0.52), and PASI100 (RR = 0.…
New data suggests that patients with obesity may see lower response rates to certain biologic treatments for psoriasis.
Jul 22, 2026
Calcium signaling dysregulation drives keratinocyte defects and immune activation in psoriasis
Allergy & Immunology Sys. Review
Calcium signaling dysregulation drives keratinocyte defects and immune activation in psoriasis Calcium signaling problems may drive the cycle of psoriasis
This systematic review synthesizes evidence that impaired calcium sensing and SOCE dysfunction in keratinocytes, alongside persistently acti…
New research identifies how faulty calcium signals in skin cells and immune cells could be a key driver of psoriasis symptoms.
Frontiers Jul 15, 2026
Combination therapies of plant-derived compounds outperform monotherapy for psoriasis vulgaris with specific immunological profiles
Rheumatology Meta-analysis
Combination therapies of plant-derived compounds outperform monotherapy for psoriasis vulgaris with specific immunological profiles Plant compounds combined with standard care improve psoriasis symptoms
This systematic review and network meta-analysis of 84 randomized controlled trials involving 7,544 patients found that combination therapie…
Combining specific plant-derived ingredients with standard treatments may offer better results for people living with psoriasis.
Frontiers Jun 22, 2026
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
Dermatology Phase III
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis New injection shows promise for moderate to severe plaque psoriasis
This phase 3 randomized trial in 770 patients with moderate-to-severe plaque psoriasis found that SSGJ-608 (80mg every 2 weeks or 160mg ever…
A new injectable treatment showed high success rates in clearing skin and improving appearance for people with plaque psoriasis.
Frontiers Jun 10, 2026

Questions about Psoriasis

Are there regional differences in health issues for people with psoriasis?

Yes, regional differences exist in psoriasis-related health issues, including comorbidities, treatment patterns, and healthcare access, as shown by studies from North America, Europe, Asia, and Africa.

Full answer →
Is secukinumab effective for Chinese patients with psoriatic arthritis?

Yes, secukinumab is effective for Chinese patients with psoriatic arthritis, with real-world data and cost-effectiveness analyses supporting its use.

Full answer →